Indeed, inhibition of EFGR/Src/Akt signaling with EFGR inhibitor gefitinib, Src inhibitor dasatinib, and Akt inhibitor LY294002 specifically decreased SOX2 expression in NSCLC H1650SP-Adh CSCs [478]. The gene discussed is SRC; the disease is non-small cell lung carcinoma.